Loading...
Docoh

Insulet (PODD)

Insulet Corporation , headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

Company profile

Ticker
PODD
Exchange
CEO
Shacey Petrovic
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Insulet Asia (Singapore) Pte. Ltd. • Insulet Austria GmbH • Insulet Australia Pty Ltd • Insulet Canada Corporation • Insulet Consulting (Shenzhen) Co., Ltd. • Insulet France SAS • Insulet Germany GmbH • Insulet International Holdings Ltd. • Insulet International Ltd. • Insulet MA Securities Corporation ...
IRS number
43523891

PODD stock data

Calendar

4 Aug 22
28 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 723.8M 723.8M 723.8M 723.8M 723.8M 723.8M
Cash burn (monthly) 366.67K 12.13M 12.03M (no burn) (no burn) 3.31M
Cash used (since last report) 1.08M 35.82M 35.53M n/a n/a 9.77M
Cash remaining 722.72M 687.98M 688.27M n/a n/a 714.03M
Runway (months of cash) 1971.0 56.7 57.2 n/a n/a 215.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
24 Aug 22 Christensen Bret Common Stock Sell Dispose S No No 264.24 2,900 766.3K 19,551
1 Jul 22 Petrovic Shacey Common Stock Sell Dispose S No Yes 222.9 15,000 3.34M 13,695
1 Jul 22 Petrovic Shacey Common Stock Option exercise Acquire M No Yes 46.22 7,930 366.52K 28,695
1 Jul 22 Petrovic Shacey Common Stock Option exercise Acquire M No Yes 29.26 7,070 206.87K 20,765
1 Jul 22 Petrovic Shacey Employee Stock Option Common Stock Option exercise Dispose M No No 46.22 7,930 366.52K 25,445
1 Jul 22 Petrovic Shacey Employee Stock Option Common Stock Option exercise Dispose M No No 29.26 7,070 206.87K 0
15 Jun 22 Minogue Michael R Common Stock Gift Acquire G Yes No 0 808 0 8,921
15 Jun 22 Minogue Michael R Common Stock Gift Dispose G No No 0 808 0 1,009
6 Jun 22 Charles Alpuche Common Stock Sell Dispose S No No 215.32 6,000 1.29M 43,899
3 Jun 22 Budden Lauren Common Stock Payment of exercise Dispose F No No 212.57 366 77.8K 5,578
29.7% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 430 462 -6.9%
Opened positions 41 65 -36.9%
Closed positions 73 61 +19.7%
Increased positions 170 188 -9.6%
Reduced positions 155 154 +0.6%
13F shares Current Prev Q Change
Total value 15.48B 18.89B -18.0%
Total shares 71.03M 70.61M +0.6%
Total puts 130.5K 132.9K -1.8%
Total calls 150.4K 160.2K -6.1%
Total put/call ratio 0.9 0.8 +4.6%
Largest owners Shares Value Change
FMR 10.37M $2.26B +0.1%
Capital Research Global Investors 6.74M $1.47B -2.7%
Vanguard 6.33M $1.38B +2.0%
Wellington Management 5.16M $1.12B +53.3%
BLK Blackrock 4.74M $1.03B +6.2%
Capital World Investors 4.19M $913.22M -2.8%
TROW T. Rowe Price 3.47M $755.78M -0.7%
Clearbridge Advisors 1.67M $363.37M -1.7%
JPM JPMorgan Chase & Co. 1.43M $312.69M +4.9%
STT State Street 1.43M $310.57M -2.3%
Largest transactions Shares Bought/sold Change
Wellington Management 5.16M +1.79M +53.3%
BLK Blackrock 4.74M +275.85K +6.2%
D1 Capital Partners 1.24M -206.15K -14.3%
Capital Research Global Investors 6.74M -186.6K -2.7%
Renaissance Technologies 0 -182.9K EXIT
FIL 246.6K -178.47K -42.0%
Fred Alger Management 621.74K -161.59K -20.6%
Marshall Wace 518.58K +128.3K +32.9%
MS Morgan Stanley 624.01K +126.45K +25.4%
Vanguard 6.33M +123.94K +2.0%

Financial report summary

?
Risks
  • We currently rely on sales of the Omnipod System, and tailored versions of the Omnipod System in our drug delivery product line, to generate nearly all our revenue.
  • If we fail to expand and maintain an effective sales force or successfully develop our relationships with intermediaries, our business, prospects and brand may be materially and adversely affected.
  • Our ability to grow our revenue depends in part on our retaining a high percentage of our customers.
  • If we do not effectively manage our growth, our business resources may become strained and we may not be able to deliver the Omnipod System in a timely manner, which could harm our results of operations.
  • Failure to secure or retain adequate coverage or reimbursement for our products by third-party payors could adversely affect our business, financial condition and results of operations.
  • Healthcare reform laws could adversely affect our revenue and financial condition.
  • We face competition from numerous competitors, many of whom have far greater resources than we have, and, as a result, we may not be able to compete effectively.
  • Technological breakthroughs in diabetes monitoring, treatment or prevention could render the Omnipod System obsolete.
  • Our own new product development initiatives may prove to be ineffective or not commercially successful.
  • Future market or clinical studies may be unfavorable to the Omnipod System and its efficacy, which could hinder our sales efforts and have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • We may be unable to adequately protect our intellectual property rights.
  • Claims that our current or future products infringe or misappropriate the proprietary rights of others could adversely affect our ability to sell those products and cause us to incur additional costs.
  • Our financial condition and results of operations have been and may to continue to be adversely affected by the COVID-19 pandemic.
  • Our financial condition or results of operations may be adversely affected by international business risks.
  • Our Omnipod System inventory is produced and maintained in a limited number of locations.
  • If we are unable to obtain sufficient components or raw materials on a timely basis or if we experience manufacturing difficulties, including not effectively managing the start-up of new manufacturing lines, our business may be harmed.
  • We are dependent upon third-party suppliers, making us vulnerable to supply problems and price fluctuations.
  • We rely on agreements or licenses to intellectual property or other rights in order to sell our current product and commercialize new products.
  • Our non-insulin drug delivery product line faces challenges which, if not met, may impair its future success.
  • We are subject to extensive government regulation, which could restrict the sales and marketing of our products and could cause us to incur significant costs.
  • Malfunction of our products could lead to recalls or safety alerts and have a significant adverse impact on us.
  • We may be subject to enforcement action if we engage in improper marketing or promotion of our products.
  • The medical device industry is heavily regulated. If we fail to comply with all applicable laws and government regulations, we could be subject to substantial penalties and/or be excluded from participation in government programs.
  • We are subject to complex and evolving laws and regulations regarding privacy and data protection, many of which are subject to change and uncertain interpretation, which could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.
  • We rely on the proper function, availability and security of our product and information technology systems and a successful cyber-attack or other breach or disruption of our product or these systems could have a material adverse effect on our business and results of operations.
  • Failure to maintain the privacy and security of our customer, third-party payor, employee, supplier or Company information could result in substantial costs and/or subject us to litigation, enforcement actions and reputational damage.
  • We may not be able to generate sufficient cash flow from operations to service our debt, which is substantial.
  • Our Credit Agreement imposes restrictions on us that may adversely affect our ability to operate our business.
  • Conversion of any of our Convertible Senior Notes may dilute the ownership interest of existing stockholders or depress our stock price.
  • Our success depends on our ability to attract, motivate, and retain key personnel.
  • Acquisitions or investments in new businesses, products or technologies could disrupt our business.
  • We may need to raise additional funds in the future, and these funds may not be available on acceptable terms or at all.
  • The price of our common stock may be volatile.
Management Discussion
  • Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • We are primarily engaged in the development, manufacture and sale of our proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time; and its wireless companion, the handheld PDM/Controller. The Omnipod System, which features discreet and easy-to-use devices, communicates wirelessly, provides for virtually pain-free automated cannula insertion and eliminates the need for MDI therapy or the use of pump and tubing. We believe that the Omnipod System’s unique proprietary design and features allow people with insulin-dependent diabetes to manage their diabetes with unprecedented freedom, comfort, convenience and ease.
  • In addition to the diabetes market space, we have partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. Most of our drug delivery revenue currently consists of sales of pods to Amgen for use in the Neulasta® Onpro® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: advisory, battery, borrowing, broke, dispute, France, ground, mutual, ramp, redundancy, resolution, resolve, retail, sue, suit
Removed: Board, defend, demand, determine, estimate, injunctive, October, order, PDM, realized, relief, Rule, set, taxable, vigorously

Patents